MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the sale, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

MaxCyte Stock Up 1.1 %

MaxCyte stock traded up $0.04 during trading hours on Wednesday, hitting $3.74. The stock had a trading volume of 410,809 shares, compared to its average volume of 532,271. The business’s 50 day simple moving average is $4.17 and its 200-day simple moving average is $4.26. The stock has a market cap of $392.04 million, a price-to-earnings ratio of -10.57 and a beta of 1.40. MaxCyte, Inc. has a one year low of $2.45 and a one year high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. Research analysts anticipate that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Several institutional investors and hedge funds have recently made changes to their positions in MXCT. Mudita Advisors LLP boosted its stake in shares of MaxCyte by 35.3% during the 4th quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock worth $8,842,000 after acquiring an additional 490,491 shares during the last quarter. Cadian Capital Management LP bought a new position in shares of MaxCyte during the 4th quarter valued at about $26,531,000. PNC Financial Services Group Inc. bought a new position in shares of MaxCyte during the 4th quarter valued at approximately $29,000. Salem Investment Counselors Inc. increased its holdings in shares of MaxCyte by 104.0% in the 1st quarter. Salem Investment Counselors Inc. now owns 56,375 shares of the company’s stock worth $236,000 after buying an additional 28,741 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of MaxCyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock valued at $83,000 after purchasing an additional 7,898 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.